TLDR Biotech aims to be your one-stop source for biotech and pharma updates - all with one daily email.

I’m always looking to make these news compilations more informative, impactful, and easy to navigate.

So if you have any feedback on what you like (or don’t), I’d love to hear from you! 📣

And if you like these newsletters and think a friend or colleague would benefit, please share this with them! ♻️

(You can also reach out to me on LinkedIn)

MINOR HOUSEKEEPING
How these updates are formatted

The newsletter is split into three main sections:

• THE GOOD - good news (eg. fundraises, product approvals)

• THE BAD - negative news (eg. clinical trial failures, layoffs)

• THE UGLY - negative but atypical news (lawsuits, product recalls, scandals)

Within each of the three above parts, there are additional sections for easier navigation:

• Eg. There will be multiple “The Good” sections covering things like Fundraises, Approvals, Partnerships etc.

• There will be also additional tags within these sections (Eg. fundraises may mention Stage, product approvals may mention drug name and disease area.)

See something you want to get into further? Click the Read More (goes out to either a news article or a press release).

One last thing; I know paywalls can be annoying, so there’s a [Paywall] tag for any news stories behind one.

ENJOYING THESE NEWSLETTERS?
Consider an optional paid subscription.

TLDR Biotech is currently a one-person show that works full-time to put together these compilations and related content.

If you’re getting value out of these daily compilations, please consider a paid subscription (only $5/month) to support my continued work on this project.

THE GOOD
Approvals & Labels

After 34 years, Geron lands it’s first FDA approval
Oligonucleotide, blood cancer, anemia, myelodysplastic syndromes - Read more

Abbot’s pacemaker nabs European CE mark approval
Medical device, pacemaker - Read more

THE GOOD
Clinical Trials

Arbutus BioPharma published positive Ph2a results
RNAi, chronic hepatitis B virus (cHBV) infection - Read more

THE GOOD
Fundraises

Mindset Medical Series A (amount undisclosed)
Software as a medical device, virtual health - Read more

THE GOOD
Investments

PharmaCord gets investment from Permira
Pharma services, commercialization - Read more

Vetter plots Illinois and Germany-based expansions
CDMO, fill-finish, manufacturing - Read more

THE GOOD
IPOs

Super Size Me; Rapport Therapeutics ups IPO to $154M
Small molecule, focal epilepsy, peripheral neuropathic pain, bipolar disorder - Read more

THE GOOD
Lawsuits

New Jersey district judge dismisses antitrust suit against Bristol Myers Squibb
Insurance, anticompetitive - Read more [Paywall]

THE GOOD
Market Reports

Eli Lilly may topple Eisai, Biogen’s Alzheimer’s throne
Monoclonal antibody, Alzheimer’s - Read more

SPONSORED
Did you know that the smaller batches are the most precious ones? 🤔

Don’t be shy of your batch size! 

Unlock the potential of your small batch production with White Raven! 

Learn how to unleash the full potential of your batch here! 

White Raven is dedicated to the production of small batches and provides solutions that are customized to suit your unique product’s needs.

THE GOOD
Mergers & Acquisitions

Karl Storz to acquire Asensus Surgical
Surgery robots, medical device, medtech - Read more

THE GOOD
Partnerships

Corden Pharma partners with Certest Biotec
LNPs, ionizable lipids, CDMO - Read more

Ipsen partners with Marengo Therapeutics
Undislosed upfront fee, $1.2B in biobucks
Antibody, T-cell engager, cancer - Read more

THE GOOD
Regulatory

Abbvie and Alphabet’s Calico Therapeutics rare disease drug chosen for FDA rare disease pilot
Small molecule, vanishing white matter disease - Read more

THE GOOD
Research

NIH invests in pilot to bring clinical research to primary care offices
Clinical research, primary care - Read more [Paywall]

THE BAD
Opinions

After FDA panel’s teardown of Lykos Therapeutic’s MDMA prospects, what happens next?
MDMA, psychedelics, post-traumatic stress disorder (PTSD) - Read more

THE BAD
Patient Access

Can biosimilars survive in the US? Doubts raised as Abbvie’s Humira continues market hold
Biosimilars, antibody - Read more [Paywall]

THE UGLY
Clinical Trials

Biomea Fusion slapped with FDA full clinical hold
Small molecule, diabetes - Read more

THE UGLY
Criminal Acts

Former Takeda employee hit with wire fraud charges, scammed company out of $2.3M
Wire fraud, consulting, scam - Read more

THE UGLY
Politics & Policy

Biosecure Act might be coming for drug developers directly? Legend Biotech on watch
Biosecurity, national security - Read more

THE UGLY
Withdrawals & Recalls

Medtronic hit with FDA Class 1 recall over inaccurate software measurements
Brain surgery, software - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣 

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Want to sponsor this newsletter and reach an audience of 300+ biotech and pharma professionals? Reach us here. 👍

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here.